Cargando…
Tumor metabolic volume by (18)F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50%
There is a lack of markers for predicting favorable outcomes after pembrolizumab therapy in patients with non-small cell lung cancer (NSCLC) with programmed death ligand-1 (PD-L1) expression ≥ 50%. This retrospective study examined the prognostic significance of 2-deoxy-2-[18F] fluoro-d-glucose ((18...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7490347/ https://www.ncbi.nlm.nih.gov/pubmed/32929123 http://dx.doi.org/10.1038/s41598-020-71735-y |
_version_ | 1783582022224052224 |
---|---|
author | Yamaguchi, Ou Kaira, Kyoichi Hashimoto, Kosuke Mouri, Atsuto Shiono, Ayako Miura, Yu Murayama, Yoshitake Kobayashi, Kunihiko Kagamu, Hiroshi Kuji, Ichiei |
author_facet | Yamaguchi, Ou Kaira, Kyoichi Hashimoto, Kosuke Mouri, Atsuto Shiono, Ayako Miura, Yu Murayama, Yoshitake Kobayashi, Kunihiko Kagamu, Hiroshi Kuji, Ichiei |
author_sort | Yamaguchi, Ou |
collection | PubMed |
description | There is a lack of markers for predicting favorable outcomes after pembrolizumab therapy in patients with non-small cell lung cancer (NSCLC) with programmed death ligand-1 (PD-L1) expression ≥ 50%. This retrospective study examined the prognostic significance of 2-deoxy-2-[18F] fluoro-d-glucose ((18)F-FDG) uptake as a predictive marker of first-line pembrolizumab. Forty-eight patients with previously untreated NSCLC and PD-L1 expression levels ≥ 50% who underwent (18)F-FDG-positron emission tomography (PET) just before administration of pembrolizumab monotherapy were eligible and underwent assessment of metabolic tumor volume (MTV), total lesion glycolysis (TLG), and maximum of standardized uptake value (SUV(max)) on (18)F-FDG uptake. The objective response rate, median progression-free survival, and median overall survival were 51.1%, 7.1 months, and 18.6 months, respectively. In univariate survival analyses, high MTV was barely a significant prognostic predictor and was confirmed as an independent factor linked to worse outcomes in multivariate analysis, predominantly in patients with a histological diagnosis of adenocarcinoma. A high MTV was significantly associated with distant metastases (especially bone metastasis), C-reactive protein (CRP) level, and PD-L1 expression ≥ 75%. Metabolic tumor activity assessed as MTV from (18)F-FDG uptake predicted the prognosis after first-line pembrolizumab treatment in patients with NSCLC and PD-L1 expression ≥ 50%, especially for adenocarcinoma. |
format | Online Article Text |
id | pubmed-7490347 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-74903472020-09-16 Tumor metabolic volume by (18)F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50% Yamaguchi, Ou Kaira, Kyoichi Hashimoto, Kosuke Mouri, Atsuto Shiono, Ayako Miura, Yu Murayama, Yoshitake Kobayashi, Kunihiko Kagamu, Hiroshi Kuji, Ichiei Sci Rep Article There is a lack of markers for predicting favorable outcomes after pembrolizumab therapy in patients with non-small cell lung cancer (NSCLC) with programmed death ligand-1 (PD-L1) expression ≥ 50%. This retrospective study examined the prognostic significance of 2-deoxy-2-[18F] fluoro-d-glucose ((18)F-FDG) uptake as a predictive marker of first-line pembrolizumab. Forty-eight patients with previously untreated NSCLC and PD-L1 expression levels ≥ 50% who underwent (18)F-FDG-positron emission tomography (PET) just before administration of pembrolizumab monotherapy were eligible and underwent assessment of metabolic tumor volume (MTV), total lesion glycolysis (TLG), and maximum of standardized uptake value (SUV(max)) on (18)F-FDG uptake. The objective response rate, median progression-free survival, and median overall survival were 51.1%, 7.1 months, and 18.6 months, respectively. In univariate survival analyses, high MTV was barely a significant prognostic predictor and was confirmed as an independent factor linked to worse outcomes in multivariate analysis, predominantly in patients with a histological diagnosis of adenocarcinoma. A high MTV was significantly associated with distant metastases (especially bone metastasis), C-reactive protein (CRP) level, and PD-L1 expression ≥ 75%. Metabolic tumor activity assessed as MTV from (18)F-FDG uptake predicted the prognosis after first-line pembrolizumab treatment in patients with NSCLC and PD-L1 expression ≥ 50%, especially for adenocarcinoma. Nature Publishing Group UK 2020-09-14 /pmc/articles/PMC7490347/ /pubmed/32929123 http://dx.doi.org/10.1038/s41598-020-71735-y Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Yamaguchi, Ou Kaira, Kyoichi Hashimoto, Kosuke Mouri, Atsuto Shiono, Ayako Miura, Yu Murayama, Yoshitake Kobayashi, Kunihiko Kagamu, Hiroshi Kuji, Ichiei Tumor metabolic volume by (18)F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50% |
title | Tumor metabolic volume by (18)F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50% |
title_full | Tumor metabolic volume by (18)F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50% |
title_fullStr | Tumor metabolic volume by (18)F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50% |
title_full_unstemmed | Tumor metabolic volume by (18)F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50% |
title_short | Tumor metabolic volume by (18)F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50% |
title_sort | tumor metabolic volume by (18)f-fdg-pet as a prognostic predictor of first-line pembrolizumab for nsclc patients with pd-l1 ≥ 50% |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7490347/ https://www.ncbi.nlm.nih.gov/pubmed/32929123 http://dx.doi.org/10.1038/s41598-020-71735-y |
work_keys_str_mv | AT yamaguchiou tumormetabolicvolumeby18ffdgpetasaprognosticpredictoroffirstlinepembrolizumabfornsclcpatientswithpdl150 AT kairakyoichi tumormetabolicvolumeby18ffdgpetasaprognosticpredictoroffirstlinepembrolizumabfornsclcpatientswithpdl150 AT hashimotokosuke tumormetabolicvolumeby18ffdgpetasaprognosticpredictoroffirstlinepembrolizumabfornsclcpatientswithpdl150 AT mouriatsuto tumormetabolicvolumeby18ffdgpetasaprognosticpredictoroffirstlinepembrolizumabfornsclcpatientswithpdl150 AT shionoayako tumormetabolicvolumeby18ffdgpetasaprognosticpredictoroffirstlinepembrolizumabfornsclcpatientswithpdl150 AT miurayu tumormetabolicvolumeby18ffdgpetasaprognosticpredictoroffirstlinepembrolizumabfornsclcpatientswithpdl150 AT murayamayoshitake tumormetabolicvolumeby18ffdgpetasaprognosticpredictoroffirstlinepembrolizumabfornsclcpatientswithpdl150 AT kobayashikunihiko tumormetabolicvolumeby18ffdgpetasaprognosticpredictoroffirstlinepembrolizumabfornsclcpatientswithpdl150 AT kagamuhiroshi tumormetabolicvolumeby18ffdgpetasaprognosticpredictoroffirstlinepembrolizumabfornsclcpatientswithpdl150 AT kujiichiei tumormetabolicvolumeby18ffdgpetasaprognosticpredictoroffirstlinepembrolizumabfornsclcpatientswithpdl150 |